share_log

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K: Current report

Mangoceuticals | 8-K：重大事件
美股SEC公告 ·  03/26 17:31
Moomoo AI 已提取核心信息
On March 25, 2024, Mangoceuticals, Inc. held a Special Meeting where stockholders approved significant proposals, including a reverse stock split and an amendment to the company's Equity Incentive Plan. The reverse stock split, which was approved by approximately 91% of votes, allows the Board of Directors to consolidate shares at a ratio between one-for-two and one-for-fifty, at their discretion, anytime before March 25, 2025. Additionally, the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan was approved, which includes an 'evergreen' provision allowing for an automatic increase in the number of shares available for awards annually for nine years, starting April 1, 2024. The plan provides various equity awards to employees, officers, directors, and consultants, with a cap of 26,000,000 shares for issuance or grants under the plan in total, and the same amount for Incentive Stock Options. The meeting saw a quorum with 74.1% of the voting shares present, and all proposals described in the Proxy Statement filed on March 1, 2024, were approved.
On March 25, 2024, Mangoceuticals, Inc. held a Special Meeting where stockholders approved significant proposals, including a reverse stock split and an amendment to the company's Equity Incentive Plan. The reverse stock split, which was approved by approximately 91% of votes, allows the Board of Directors to consolidate shares at a ratio between one-for-two and one-for-fifty, at their discretion, anytime before March 25, 2025. Additionally, the First Amendment to the Mangoceuticals, Inc. 2022 Equity Incentive Plan was approved, which includes an 'evergreen' provision allowing for an automatic increase in the number of shares available for awards annually for nine years, starting April 1, 2024. The plan provides various equity awards to employees, officers, directors, and consultants, with a cap of 26,000,000 shares for issuance or grants under the plan in total, and the same amount for Incentive Stock Options. The meeting saw a quorum with 74.1% of the voting shares present, and all proposals described in the Proxy Statement filed on March 1, 2024, were approved.
2024年3月25日，Mangoceuticals, Inc.举行了一次特别会议，股东们批准了重要提案，包括反向股票拆分和公司股权激励计划的修正案。反向股票拆分获得了大约 91% 的选票的批准，允许董事会在2025年3月25日之前的任何时候自行决定以一比二和一比五的比例合并股份。此外，Mangoceuticals, Inc. 2022年股权激励计划的第一修正案获得批准，其中包括一项 “常青” 条款，允许自2024年4月1日起在九年内自动增加每年可供奖励的股票数量。该计划向员工、高级职员、董事和顾问提供各种股权奖励，根据该计划总发行或赠款的上限为26,000,000股，激励性股票期权的上限为相同金额。会议达到了法定人数，有74.1％的有表决权的股份出席，2024年3月1日提交的委托书中描述的所有提案均获得批准。
2024年3月25日，Mangoceuticals, Inc.举行了一次特别会议，股东们批准了重要提案，包括反向股票拆分和公司股权激励计划的修正案。反向股票拆分获得了大约 91% 的选票的批准，允许董事会在2025年3月25日之前的任何时候自行决定以一比二和一比五的比例合并股份。此外，Mangoceuticals, Inc. 2022年股权激励计划的第一修正案获得批准，其中包括一项 “常青” 条款，允许自2024年4月1日起在九年内自动增加每年可供奖励的股票数量。该计划向员工、高级职员、董事和顾问提供各种股权奖励，根据该计划总发行或赠款的上限为26,000,000股，激励性股票期权的上限为相同金额。会议达到了法定人数，有74.1％的有表决权的股份出席，2024年3月1日提交的委托书中描述的所有提案均获得批准。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息